Novel Delivery Systems for Interferons

Hamidi, Mehrdad; Zarrin, Abdolhossein; Foroozesh, Mahshid

doi:10.1080/07388550701503410

Cited by 9 publications

(8 citation statements)

References 116 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IFNγ is one of such pharmaceuticals that is now used for CGD and malignant osteopetrosis 1. Type I IFNs, such as IFNα and IFNβ, have a variety of products used in the clinical practice,5 but few attempts such as chemical conjugation have been made to reduce the clearance of IFNγ from the body. This may be because of the fact that, unlike the type I IFNs, IFNγ is a homodimeric protein 23,24.…”

Section: Disccusionmentioning

confidence: 99%

See 1 more Smart Citation

Testicular cancer mortality in the Americas, 1980–2003

Bertuccio

Malvezzi

Chatenoud

et al. 2007

Cancer

View full text Add to dashboard Cite

In this study, we developed a mathematical model for olefin copolymerization using soluble Ziegler–Natta catalysts in a semibatch reactor to predict the reaction rate and polymer characteristics (i.e., molecular weight, polydispersity, and ethylene content) as functions of the reaction parameters (i.e., time, temperature, pressure, concentrations, and so on) accurately. The proposed model differs from others because it considers the olefin copolymerization as a dynamic process and applies double moments for two reactants (ethylene and propylene) in the presence of hydrogen. To establish the model validity, the copolymerization was performed with VOCl3Al2Et3Cl3 systems with hydrogen as a molecular weight controlling agent. The dynamic model was able to reproduce the experimental data within experimental accuracy and accurately demonstrated the fundamental importance of the polymerization variables on the final properties of the polymer material in the copolymerization of ethylene and propylene with Al/V ratios of up to 28 before synthesis. © 2006 Wiley Periodicals, Inc. J Appl Polym Sci 100: 3101–3110, 2006

show abstract

Section: Disccusionmentioning

confidence: 99%

“…Although a number of technologies have been developed to prolong the short in vivo half‐life of cytokines or other protein drugs, a few systems have been designed or intended to use for IFNγ 5. The most studied system to extend the half‐life of protein drugs is controlled release formulations.…”

Section: Introductionmentioning

confidence: 99%

Testicular cancer mortality in the Americas, 1980–2003

Bertuccio

Malvezzi

Chatenoud

et al. 2007

Cancer

View full text Add to dashboard Cite

show abstract

“…The lung is especially well suited for this unique therapeutic nanoplex delivery strategy as direct contact with the environment provides a portal for inhalation administration, avoiding parenteral injection. In particular, site-specific delivery of type I IFN or IFN inducers can potentially reduce systemic side effects (41,42), in addition to having a beneficial therapeutic outcome of reducing influenza virus replication.…”

Section: Discussionmentioning

confidence: 99%

Gold nanorod delivery of an ssRNA immune activator inhibits pandemic H1N1 influenza viral replication

Chakravarthy

Bonoiu

Davis

et al. 2010

Proc. Natl. Acad. Sci. U.S.A.

101

View full text Add to dashboard Cite

The emergence of the pandemic 2009 H1N1 influenza virus has become a world-wide health concern. As drug resistance appears, a new generation of therapeutic strategies will be required. Here, we introduce a nanotechnology approach for the therapy of pan-demic and seasonal influenza virus infections. This approach uses gold nanorods (GNRs) to deliver an innate immune activator, pro-ducing a localized therapeutic response. We demonstrated the utility of a biocompatible gold nanorod, GNR-5′PPP-ssRNA nanoplex, as an antiviral strategy against type A influenza virus. In human respiratory bronchial epithelial cells, this nanoplex activated the retinoic acid-inducible gene I (RIG-I) pathogen recognition pathway, resulting in increased expression of IFN-β and other IFN-stimulated genes (ISGs) (e.g., PKR, MDA5, IRF1, IRF7, and MX1 ). This increase in type I IFN and ISGs resulted in a decrease in the replication of H1N1 influenza viruses. These findings suggest that further evaluation of biocompatible nanoplexes as unique antivirals for treatment of seasonal and pandemic influenza viruses is warranted.

show abstract

“…4 Although a number of technologies have been developed to prolong the short in vivo half-life of cytokines or other protein drugs, a few systems have been designed or intended to use for IFN(. 5 The most studied system to extend the half-life of protein drugs is controlled release formulations. Fujioka et al 6,7 developed mini-pellets that continuously release IFN" for more than 1 week after subcutaneous implantation.…”

Section: Introductionmentioning

confidence: 99%